Drug intelligence / Profile preview

D326

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical

Overview

D326 is a drug component currently under investigation as part of combination therapies, specifically CKD-348 and CKD-386. These combinations are being studied for the treatment of essential hypertension, dyslipidemia, and Type 2 Diabetes Mellitus. Clinical trials have evaluated its pharmacokinetic properties and drug interactions when co-administered with other agents in healthy subjects. The precise mechanism of action for D326 as an individual component is not detailed in the provided context.

Beyond the preview

Go deeper on D326.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D326.

Explore the full profile